These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2694203)

  • 21. Noradrenergic function and the cortisol response to dexamethasone in depression.
    Rubin AL; Price LH; Charney DS; Heninger GR
    Psychiatry Res; 1985 May; 15(1):5-15. PubMed ID: 2989963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sex differences in the association between obsessive-compulsive symptom dimensions and diurnal cortisol patterns.
    Labad J; Melia CS; Segalàs C; Alonso P; Salvat-Pujol N; Real E; Ferrer Á; Jiménez-Murcia S; Soriano-Mas C; Soria V; Menchón JM
    J Psychiatr Res; 2021 Jan; 133():191-196. PubMed ID: 33352399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elevated thyroid indices in children and adolescents with obsessive-compulsive disorder: effects of clomipramine treatment.
    McCracken JT; Hanna GL
    J Child Adolesc Psychopharmacol; 2005 Aug; 15(4):581-7. PubMed ID: 16190790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clomipramine and obsessive compulsive disorder: a placebo-controlled double-blind study of 32 patients.
    Greist JH; Jefferson JW; Rosenfeld R; Gutzmann LD; March JS; Barklage NE
    J Clin Psychiatry; 1990 Jul; 51(7):292-7. PubMed ID: 2195006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The hypothalamic-pituitary-adrenal system in panic disorder.
    Goldstein S; Halbreich U; Asnis G; Endicott J; Alvir J
    Am J Psychiatry; 1987 Oct; 144(10):1320-3. PubMed ID: 3661766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tricyclic response in obsessive compulsive disorder.
    Insel TR; Mueller EA; Gillin JC; Siever LJ; Murphy DL
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(1):25-31. PubMed ID: 3991911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cortisol as an indicator of hypothalmic-pitituary-adrenal axis dysregulation in patients with panic disorder: a literature review.
    Jakuszkowiak-Wojten K; Landowski J; Wiglusz MS; Cubała WJ
    Psychiatr Danub; 2015 Sep; 27 Suppl 1():S445-51. PubMed ID: 26417813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suppression of cortisol following dexamethasone in demented patients.
    Charles GA; Lefevre A; Mirel J; Rush AJ
    Psychiatry Res; 1986 Mar; 17(3):173-82. PubMed ID: 3704025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment.
    Zohar J; Insel TR; Zohar-Kadouch RC; Hill JL; Murphy DL
    Arch Gen Psychiatry; 1988 Feb; 45(2):167-72. PubMed ID: 3276283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biological markers in obsessive-compulsive and affective disorders.
    Insel TR; Mueller EA; Gillin JC; Siever LJ; Murphy DL
    J Psychiatr Res; 1984; 18(4):407-23. PubMed ID: 6512711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma postdexamethasone cortisol levels in schizoaffective disorder.
    Meador-Woodruff JH; Greden JF; Grunhaus L; Haskett RF
    Psychiatry Res; 1988 Oct; 26(1):35-42. PubMed ID: 3237905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypothalamic-pituitary-adrenocortical function in mixed and pure mania.
    Swann AC; Stokes PE; Casper R; Secunda SK; Bowden CL; Berman N; Katz MM; Robins E
    Acta Psychiatr Scand; 1992 Apr; 85(4):270-4. PubMed ID: 1595360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The dexamethasone suppression and metyrapone tests in depression.
    Morphy MA; Fava GA; Perini GI; Molnar G; Zielezny M; Lisansky J
    Psychiatry Res; 1985 Jun; 15(2):153-8. PubMed ID: 3862146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of specific association between panicogenic properties of caffeine and HPA-axis activation. A placebo-controlled study of caffeine challenge in patients with panic disorder.
    Masdrakis VG; Markianos M; Oulis P
    Psychiatry Res; 2015 Sep; 229(1-2):75-81. PubMed ID: 26243374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathophysiology of HPA axis abnormalities in patients with major depression: an update.
    Kathol RG; Jaeckle RS; Lopez JF; Meller WH
    Am J Psychiatry; 1989 Mar; 146(3):311-7. PubMed ID: 2645793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of axis II diagnoses on treatment outcome with clomipramine in 55 patients with obsessive-compulsive disorder.
    Baer L; Jenike MA; Black DW; Treece C; Rosenfeld R; Greist J
    Arch Gen Psychiatry; 1992 Nov; 49(11):862-6. PubMed ID: 1444723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A clomipramine dosage reduction study in the course of long-term treatment of obsessive-compulsive disorder patients.
    Pato MT; Hill JL; Murphy DL
    Psychopharmacol Bull; 1990; 26(2):211-4. PubMed ID: 2236458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypothalamic-pituitary-adrenal axis activity and tricyclic response in major depression.
    Nelson WH; Orr WW; Stevenson JM; Shane SR
    Arch Gen Psychiatry; 1982 Sep; 39(9):1033-6. PubMed ID: 7115012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pretreatment DST and hypothalamic-pituitary-adrenocortical function in depressed patients and comparison groups. A multicenter study.
    Stokes PE; Stoll PM; Koslow SH; Maas JW; Davis JM; Swann AC; Robins E
    Arch Gen Psychiatry; 1984 Mar; 41(3):257-67. PubMed ID: 6367690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results.
    Pigott TA; Pato MT; Bernstein SE; Grover GN; Hill JL; Tolliver TJ; Murphy DL
    Arch Gen Psychiatry; 1990 Oct; 47(10):926-32. PubMed ID: 2222131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.